A review of the therapeutic potential of histone deacetylase inhibitors in rhabdomyosarcoma
This review aims to summarize the putative role of histone deacetylases (HDACs) in rhabdomyosarcoma (RMS) and the effects of HDAC inhibitors (HDACi) on RMS by elucidating and highlighting known oncogenic pathways, mechanisms of resistance, and the synergistic potential of histone deacetylase inhibit...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-08-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1244035/full |
| _version_ | 1797741276563505152 |
|---|---|
| author | Omar Selim Clara Song Amy Kumar Rebecca Phelan Arun Singh Noah Federman Noah Federman Noah Federman |
| author_facet | Omar Selim Clara Song Amy Kumar Rebecca Phelan Arun Singh Noah Federman Noah Federman Noah Federman |
| author_sort | Omar Selim |
| collection | DOAJ |
| description | This review aims to summarize the putative role of histone deacetylases (HDACs) in rhabdomyosarcoma (RMS) and the effects of HDAC inhibitors (HDACi) on RMS by elucidating and highlighting known oncogenic pathways, mechanisms of resistance, and the synergistic potential of histone deacetylase inhibitors. We searched two databases (PubMed and Google Scholar) for the keywords “Rhabdomyosarcoma, histone deacetylase, histone deacetylase inhibitors.” We excluded three publications that did not permit access to the full text to review and those that focus exclusively on pleiomorphic RMS in adults. Forty-seven papers met the inclusion criteria. This review highlights that HDACi induce cytotoxicity, cell-cycle arrest, and oxidative stress in RMS cells. Ultimately, HDACi have been shown to increase apoptosis and the cessation of embryonal and alveolar RMS proliferation in vivo and in vitro, both synergistically and on its own. HDACi contain potent therapeutic potential against RMS. This review discusses the significant findings and the biological mechanisms behind the anti-cancer effects of HDACi. Additionally, this review highlights important clinical trials assessing the efficacy of HDACi in sarcomas. |
| first_indexed | 2024-03-12T14:24:29Z |
| format | Article |
| id | doaj.art-96c376fbfead48ff8845ba8a1ea76b0a |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-03-12T14:24:29Z |
| publishDate | 2023-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-96c376fbfead48ff8845ba8a1ea76b0a2023-08-18T11:18:11ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2023-08-011310.3389/fonc.2023.12440351244035A review of the therapeutic potential of histone deacetylase inhibitors in rhabdomyosarcomaOmar Selim0Clara Song1Amy Kumar2Rebecca Phelan3Arun Singh4Noah Federman5Noah Federman6Noah Federman7Clinical and Translational Science Institute, University of California, Los Angeles, CA, United StatesClinical and Translational Science Institute, University of California, Los Angeles, CA, United StatesClinical and Translational Science Institute, University of California, Los Angeles, CA, United StatesClinical and Translational Science Institute, University of California, Los Angeles, CA, United StatesDepartment of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, United StatesClinical and Translational Science Institute, University of California, Los Angeles, CA, United StatesDepartment of Pediatrics, David Geffen School of Medicine, University of California, Los Angeles, CA, United StatesDepartment of Orthopaedic Surgery, David Geffen School of Medicine, University of California, Los Angeles, CA, United StatesThis review aims to summarize the putative role of histone deacetylases (HDACs) in rhabdomyosarcoma (RMS) and the effects of HDAC inhibitors (HDACi) on RMS by elucidating and highlighting known oncogenic pathways, mechanisms of resistance, and the synergistic potential of histone deacetylase inhibitors. We searched two databases (PubMed and Google Scholar) for the keywords “Rhabdomyosarcoma, histone deacetylase, histone deacetylase inhibitors.” We excluded three publications that did not permit access to the full text to review and those that focus exclusively on pleiomorphic RMS in adults. Forty-seven papers met the inclusion criteria. This review highlights that HDACi induce cytotoxicity, cell-cycle arrest, and oxidative stress in RMS cells. Ultimately, HDACi have been shown to increase apoptosis and the cessation of embryonal and alveolar RMS proliferation in vivo and in vitro, both synergistically and on its own. HDACi contain potent therapeutic potential against RMS. This review discusses the significant findings and the biological mechanisms behind the anti-cancer effects of HDACi. Additionally, this review highlights important clinical trials assessing the efficacy of HDACi in sarcomas.https://www.frontiersin.org/articles/10.3389/fonc.2023.1244035/fullrhabdomyosarcomahistone deacetylase inhibitorspediatric cancerclinical trialsmutations |
| spellingShingle | Omar Selim Clara Song Amy Kumar Rebecca Phelan Arun Singh Noah Federman Noah Federman Noah Federman A review of the therapeutic potential of histone deacetylase inhibitors in rhabdomyosarcoma Frontiers in Oncology rhabdomyosarcoma histone deacetylase inhibitors pediatric cancer clinical trials mutations |
| title | A review of the therapeutic potential of histone deacetylase inhibitors in rhabdomyosarcoma |
| title_full | A review of the therapeutic potential of histone deacetylase inhibitors in rhabdomyosarcoma |
| title_fullStr | A review of the therapeutic potential of histone deacetylase inhibitors in rhabdomyosarcoma |
| title_full_unstemmed | A review of the therapeutic potential of histone deacetylase inhibitors in rhabdomyosarcoma |
| title_short | A review of the therapeutic potential of histone deacetylase inhibitors in rhabdomyosarcoma |
| title_sort | review of the therapeutic potential of histone deacetylase inhibitors in rhabdomyosarcoma |
| topic | rhabdomyosarcoma histone deacetylase inhibitors pediatric cancer clinical trials mutations |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2023.1244035/full |
| work_keys_str_mv | AT omarselim areviewofthetherapeuticpotentialofhistonedeacetylaseinhibitorsinrhabdomyosarcoma AT clarasong areviewofthetherapeuticpotentialofhistonedeacetylaseinhibitorsinrhabdomyosarcoma AT amykumar areviewofthetherapeuticpotentialofhistonedeacetylaseinhibitorsinrhabdomyosarcoma AT rebeccaphelan areviewofthetherapeuticpotentialofhistonedeacetylaseinhibitorsinrhabdomyosarcoma AT arunsingh areviewofthetherapeuticpotentialofhistonedeacetylaseinhibitorsinrhabdomyosarcoma AT noahfederman areviewofthetherapeuticpotentialofhistonedeacetylaseinhibitorsinrhabdomyosarcoma AT noahfederman areviewofthetherapeuticpotentialofhistonedeacetylaseinhibitorsinrhabdomyosarcoma AT noahfederman areviewofthetherapeuticpotentialofhistonedeacetylaseinhibitorsinrhabdomyosarcoma AT omarselim reviewofthetherapeuticpotentialofhistonedeacetylaseinhibitorsinrhabdomyosarcoma AT clarasong reviewofthetherapeuticpotentialofhistonedeacetylaseinhibitorsinrhabdomyosarcoma AT amykumar reviewofthetherapeuticpotentialofhistonedeacetylaseinhibitorsinrhabdomyosarcoma AT rebeccaphelan reviewofthetherapeuticpotentialofhistonedeacetylaseinhibitorsinrhabdomyosarcoma AT arunsingh reviewofthetherapeuticpotentialofhistonedeacetylaseinhibitorsinrhabdomyosarcoma AT noahfederman reviewofthetherapeuticpotentialofhistonedeacetylaseinhibitorsinrhabdomyosarcoma AT noahfederman reviewofthetherapeuticpotentialofhistonedeacetylaseinhibitorsinrhabdomyosarcoma AT noahfederman reviewofthetherapeuticpotentialofhistonedeacetylaseinhibitorsinrhabdomyosarcoma |